Skip to main content

Clinical Trials Using Axicabtagene Ciloleucel

Review the clinical trials studying axicabtagene ciloleucel on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-16 of 16

Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Status: Active
Location: 85 locations
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
Status: Active
Location: 28 locations
Pembrolizumab with Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Patients with Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma, T-Cell Histiocyte Rich Large B-Cell Lymphoma or Epstein Barr Virus Positive Diffuse Large B-Cell Lymphoma
Status: Active
Location: 3 locations
Immune Cell Therapy (CAR-T) for the Treatment of Patients with HIV and B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 2 locations
Bridging Radiation Therapy prior to Axi-cel CAR T-Cell Therapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Itacitinib or Ruxolitinib to Improve Efficacy in Patients with Diffuse Large B-Cell Lymphoma Receiving Treatment with CAR T-cell Therapy
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients with Relapsed or Refractory Lymphoma with Exposure to High-Risk Antibiotics who are Receiving Chimeric Antigen Receptor T Cells
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Radiotherapy with Axicabtagene Ciloleucel for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Emapalumab for the Prevention of CAR-T Cell Associated Cytokine Release Syndrome in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma
Status: Active
Location: 3 locations
Glofitamab and Axicabtagene Ciloleucel as Second-Line Treatment for Patients with Relapsed or Refractory Large B-Cell Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
131I-Apamistamab Followed by Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, The IOMAB-ACT Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Axicabtagene Ciloleucel Reinfusion for the Treatment of Relapsed and/or Refractory High-Risk Non-Hodgkin Lymphoma
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
E7777 to Enhance Regulatory T-Cell Depletion Prior to CAR-T for the Treatment of Relapsed/Refractory B-Cell Lymphomas
Status: Temporarily Closed to Accrual
Location: 2 locations
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients with Non-Hodgkin Lymphoma after CAR T Cell Therapy
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Status: Enrolling by Invitation
Location: 30 locations